These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

178 related articles for article (PubMed ID: 16959678)

  • 1. Generic and commercial low molecular weight heparins.
    Messmore HL
    Clin Appl Thromb Hemost; 2006 Jul; 12(3):253. PubMed ID: 16959678
    [No Abstract]   [Full Text] [Related]  

  • 2. Product individuality of commercially available low-molecular-weight heparins and their generic versions: therapeutic implications.
    Maddineni J; Walenga JM; Jeske WP; Hoppensteadt DA; Fareed J; Wahi R; Bick RL
    Clin Appl Thromb Hemost; 2006 Jul; 12(3):267-76. PubMed ID: 16959680
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Generic low-molecular-weight heparins: some practical considerations.
    Fareed J; Leong WL; Hoppensteadt DA; Jeske WP; Walenga J; Wahi R; Bick RL
    Semin Thromb Hemost; 2004 Dec; 30(6):703-13. PubMed ID: 15630677
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Ensuring safety of biosimilar low-molecular-weight heparins: a consensus statement of the International Union of Angiology .
    Harenberg J; Kalodiki E; Walenga JM;
    Int Angiol; 2012 Apr; 31(2):101-4. PubMed ID: 22466973
    [No Abstract]   [Full Text] [Related]  

  • 5. Overview on guidelines and recommendations for generic low-molecular-weight heparins.
    Harenberg J
    Thromb Res; 2011 Feb; 127 Suppl 3():S100-4. PubMed ID: 21262425
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Development of generic low molecular weight heparins: a perspective.
    Fareed J; Leong W; Hoppensteadt DA; Jeske WP; Walenga J; Bick RL
    Hematol Oncol Clin North Am; 2005 Feb; 19(1):53-68, v-vi. PubMed ID: 15639108
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Low molecular weight heparins differ substantially: impact on developing biosimilar drugs.
    Walenga JM; Jackson CM; Kessler CM
    Semin Thromb Hemost; 2011 Apr; 37(3):322-7. PubMed ID: 21455866
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Low-molecular-weight heparin during percutaneous coronary interventions: rationale, results, and recommendations.
    Levine GN; Ferguson JJ
    Catheter Cardiovasc Interv; 2003 Oct; 60(2):185-93. PubMed ID: 14517923
    [No Abstract]   [Full Text] [Related]  

  • 9. Differentiating low-molecular-weight heparins based on chemical, biological, and pharmacologic properties: implications for the development of generic versions of low-molecular-weight heparins.
    Jeske WP; Walenga JM; Hoppensteadt DA; Vandenberg C; Brubaker A; Adiguzel C; Bakhos M; Fareed J
    Semin Thromb Hemost; 2008 Feb; 34(1):74-85. PubMed ID: 18393144
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The immunogenic potential of generic version of low-molecular-weight heparins may not be the same as the branded products.
    Fareed J; Bick RL; Rao G; Goldhaber SZ; Sasahara A; Messmore HL; Happensteadt DA; Nicolaides A; ; ; ;
    Clin Appl Thromb Hemost; 2008 Jan; 14(1):5-7. PubMed ID: 18182679
    [No Abstract]   [Full Text] [Related]  

  • 11. Structural and functional characterization of low-molecular-weight heparins: impact on the development of guidelines for generic products.
    Adiguzel C; Jeske WP; Hoppensteadt D; Walenga JM; Bansal V; Fareed J
    Clin Appl Thromb Hemost; 2009; 15(2):137-44. PubMed ID: 19357102
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Comparison of Low-Molecular-Weight Heparins Prepared From Bovine Heparins With Enoxaparin.
    Liu X; St Ange K; Fareed J; Hoppensteadt D; Jeske W; Kouta A; Chi L; Jin C; Jin Y; Yao Y; Linhardt RJ
    Clin Appl Thromb Hemost; 2017 Sep; 23(6):542-553. PubMed ID: 28056526
    [TBL] [Abstract][Full Text] [Related]  

  • 13. US Food and Drug Administration approval of generic versions of complex biologics: implications for the practicing physician using low molecular weight heparins.
    Cohen M; Jeske WP; Nicolau JC; Montalescot G; Fareed J
    J Thromb Thrombolysis; 2012 Apr; 33(3):230-8. PubMed ID: 22234748
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Low-molecular-weight heparin-induced skin necrosis: a potential association with pre-existent hypercoagulable states.
    Toll A; Gallardo F; Abella ME; Fontcuberta J; Barranco C; Pujol RM
    Int J Dermatol; 2005 Nov; 44(11):964-6. PubMed ID: 16336536
    [No Abstract]   [Full Text] [Related]  

  • 15. Generic forms of low-molecular-weight heparins: some practical considerations.
    Leong W; Hoppensteadt DA
    Clin Appl Thromb Hemost; 2003 Oct; 9(4):293-7. PubMed ID: 14653438
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Biomarkers and coagulation tests for assessing the biosimilarity of a generic low-molecular-weight heparin: results of a study in healthy subjects with enoxaparin.
    Kuczka K; Harder S; Picard-Willems B; Warnke A; Donath F; Bianchini P; Parma B; Blume H
    J Clin Pharmacol; 2008 Oct; 48(10):1189-96. PubMed ID: 18716314
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Survey of hospital policies regarding low-molecular-weight heparins.
    Schumock GT; Nutescu EA; Walton SM; Arondekar BV; Lewis RK
    Am J Health Syst Pharm; 2002 Mar; 59(6):534-8. PubMed ID: 11908246
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Generic low molecular weight heparins: a significant dilemma.
    Fareed J; Iqbal O; Nader H; Mousa S; Wahi R; Coyne E; Bick RL
    Clin Appl Thromb Hemost; 2005 Oct; 11(4):363-6. PubMed ID: 16244760
    [No Abstract]   [Full Text] [Related]  

  • 19. [Anticoagulation with low molecular weight heparins within the framework of cardioversion for atrial fibrillation].
    Tebbe U
    Dtsch Med Wochenschr; 2007 Sep; 132(39):2033-6. PubMed ID: 17882745
    [No Abstract]   [Full Text] [Related]  

  • 20. Are the current guidelines for the acceptance of generic low molecular weight heparins adequate?
    Fareed J; Bick RL
    Clin Appl Thromb Hemost; 2003 Oct; 9(4):269-72. PubMed ID: 14653436
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 9.